Monopar Therapeutics Inc.
General ticker "MNPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.2B (TTM average)
Monopar Therapeutics Inc. follows the US Stock Market performance with the rate: 39.0%.
Estimated limits based on current volatility of 3.7%: low 60.61$, high 65.24$
Factors to consider:
- Total employees count: 10 (-16.7%) as of 2023
- Top business risk factors: Limited operating history, Economic downturns and volatility, Intellectual property risks, Inexperience in new services, Cybersecurity threats
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [26.73$, 60.83$]
- 2026-12-31 to 2027-12-31 estimated range: [18.57$, 45.06$]
Financial Metrics affecting the MNPR estimates:
- Negative: with PPE of -37.3 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: Industry earnings per price (median), % of -13.66 <= 0
Short-term MNPR quotes
Long-term MNPR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.83MM | $16.16MM | $16.70MM |
| Operating Income | $-8.83MM | $-16.16MM | $-16.70MM |
| Non-Operating Income | $0.43MM | $0.58MM | $2.99MM |
| R&D Expense | $5.60MM | $13.01MM | $9.90MM |
| Income(Loss) | $-8.40MM | $-15.59MM | $-13.72MM |
| Net Income(Loss)* | $-8.40MM | $-15.59MM | $-13.72MM |
| Stockholders Equity | $5.59MM | $55.04MM | $137.83MM |
| Assets | $7.35MM | $60.29MM | $140.72MM |
| Operating Cash Flow | $-7.86MM | $-6.40MM | $-12.20MM |
| Investing Cash Flow | $4.93MM | $-14.34MM | $-63.45MM |
| Financing Cash Flow | $2.03MM | $59.29MM | $91.57MM |
| Earnings Per Share** | $-0.58 | $-1.36 | $-1.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.